Menu
Annual · values202420232022202120202019
Operating Cash Flow-33.95 M USD-33.41 M USD-43.94 M USD-57.21 M USD-43.06 M USD-52.63 M USD
Depreciation & Amortization35174 USD153301 USD207145 USD264600 USD270754 USD279234 USD
Stock-Based Compensation
Capital Expenditures20028 USD-21394 USD-84191 USD-14943 USD-68507 USD-144928 USD
Cash Flow from Investing
Cash Flow from Financing
Dividends Paid
Stock Buybacks
Free Cash Flow-31.11 M USD-34.90 M USD-46.54 M USD-57.50 M USD-39.31 M USD-52.13 M USD

Crescent Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies in the pharmaceutical sector. It specializes in advancing treatments that address significant unmet medical needs, often targeting niche or rare diseases. The company’s pipeline and research efforts aim to bring novel drug candidates through clinical development stages to improve patient outcomes. Crescent Biopharma plays a role in the broader healthcare and life sciences industry by contributing to medical innovation and therapeutic advancements. Its presence in financial markets, including listing on the Frankfurt Stock Exchange, allows investors to track its progress and financial performance as it works toward enhancing treatment options in biomedicine.